| |
The significant scientific capabilities of local talent, infrastructure and the island's decades of expertise fuel MBQ Pharma's advancement of innovative treatments for solid tumor cancers. Learn how your business can also impact the bioscience industry in Puerto Rico.
|
|
Today’s Big NewsJun 20, 2024 |
|
Tuesday, June 25, 2024 | 11am ET / 8am PT Expanded Access Programs can help deliver life-saving access to critical medications. Join us for a deep dive into the benefits of EAPs in Europe. Learn how to leverage for achieving faster access to the European market, facilitating successful commercialization, and navigating the array of regulations and guidelines. Register now.
|
|
| By Angus Liu For the first time, an HIV PrEP drug candidate has shown zero infections in a phase 3 trial. For Gilead, it serves as one of two pieces for a potential FDA filing. For GSK, it means a major competitor could be looming around the corner. |
|
|
|
By Nick Paul Taylor Jazz Pharmaceuticals hit a bum note Thursday, reporting the failure of a phase 2b essential tremor trial to meet its primary endpoint. But the drugmaker saw numeric improvements and is waiting on the data from another study rather than immediately bringing the curtain down on the program. |
By Ben Adams Not since the pre-COVID days in 2019 has a pure-play pharmaceutical company managed to win the top prize at the prestigious Cannes Lions International Festival of Creativity, as medical technology and device firms have seemingly taken over. |
By Conor Hale Designed as something of a private social network for clinicians, Polyphonic will allow users to share annotated video from procedures within their health system and tag in others for their input. |
By Zoey Becker Since its original nod in 2019, AbbVie's IL-23 inhibitor has added several new uses over the years. Now, its fourth approved disease area is ulcerative colitis. |
By Nick Paul Taylor Taysha Gene Therapies has unfurled more data in the developmental disorder Rett syndrome, linking its gene therapy to improvements in the first adults and children to receive low doses of the candidate. |
By Nick Paul Taylor UCB wants you to hear the sound of profound seizure reduction. Across a series of videos, the Belgian drugmaker makes the case that its Dravet syndrome drug Fintepla amplifies family life by allowing people to experience more seizure-free days. |
By Conor Hale The MigraineSmart program will collect patient-reported outcomes and survey responses, as well as data from wearable activity trackers—and combine them to chart the relationship between the two. |
By Kevin Dunleavy After touting the success of its intravenous (IV) formulation of Tremfya in two head-to-head trials against its own Stelara in Crohn’s disease, Johnson & Johnson has shown the success of a subcutaneous (SC) version of Tremfya in another Crohn's disease study. |
By James Waldron Thanks to a flurry of dealmaking across the Christmas period and into the new year, it sure feels like both biotechs and Big Pharma have picked up the pace when it comes to hunting down fresh assets. After crunching the data, PwC has come to the same conclusion. |
By Andrea Park Ferring Pharmaceuticals is setting the record straight on fertility issues. |
By Kevin Dunleavy Eli Lilly is stepping up its effort to combat the improper sale of compounded versions of its popular diabetes and weight loss drugs. The Indianapolis-based drugmaker is suing six wellness centers, medical spas and others that it claims are using "deceptive" advertising. |
By Nick Paul Taylor Biopharma marketing has an omnichannel problem. Almost everyone has adopted the approach but few are seeing positive effects on engagement, according to a survey, leaving the industry looking for ways to realize the promise. |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "The Top Line," journalists from Fierce Biotech and Fierce Pharma discuss the most talked-about data drops at ASCO and share on-the-ground details, including their experience with Gilead’s virtual reality Trodelvy ride. |
|
|---|
|
|
|
Wednesday, June 26, 2024 | 2pm ET/ 11am PT In this webinar, we outline a patient-centered telehealth genetic counseling model that accelerates time to meet recruitment goals by engaging and recruiting genetically eligible participants. Certified genetic counselors are uniquely qualified to support the development of a multi-phased approach to patient identification and screening, disclose genetic test results, and more. Register now.
|
|
| WebinarWatch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
| WhitepaperNew molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
| WhitepaperThis paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
